Tempus AI (NASDAQ:TEM) Stock Price Up 3.8% - Time to Buy?

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) shares rose 3.8% during trading on Wednesday . The stock traded as high as $85.27 and last traded at $85.10. Approximately 7,285,295 shares changed hands during trading, a decline of 47% from the average daily volume of 13,854,130 shares. The stock had previously closed at $81.95.

Analysts Set New Price Targets

TEM has been the topic of several research analyst reports. Needham & Company LLC reiterated a "buy" rating and issued a $56.00 price objective on shares of Tempus AI in a report on Tuesday, January 14th. William Blair lowered shares of Tempus AI from an "outperform" rating to a "market perform" rating in a research note on Wednesday, February 12th. Wolfe Research started coverage on shares of Tempus AI in a research note on Friday, December 13th. They issued an "outperform" rating and a $60.00 price objective for the company. Stifel Nicolaus downgraded shares of Tempus AI from a "buy" rating to a "hold" rating and upped their target price for the stock from $45.00 to $65.00 in a research note on Monday, November 11th. Finally, Loop Capital decreased their price target on shares of Tempus AI from $57.00 to $52.00 and set a "buy" rating for the company in a research report on Tuesday, January 14th. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $58.55.

Tempus AI Price Performance

The company's 50-day moving average price is $50.29 and its 200-day moving average price is $51.65. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69.

Insiders Place Their Bets

In other news, EVP Andrew Polovin sold 51,504 shares of the business's stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $42.39, for a total transaction of $2,183,254.56. Following the completion of the sale, the executive vice president now owns 246,085 shares in the company, valued at approximately $10,431,543.15. The trade was a 17.31 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Eric P. Lefkofsky sold 84,640 shares of the stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $80.87, for a total transaction of $6,844,836.80. Following the completion of the transaction, the chief executive officer now directly owns 4,964,820 shares in the company, valued at $401,504,993.40. This trade represents a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 2,583,467 shares of company stock valued at $130,542,311 in the last ninety days.

Institutional Trading of Tempus AI

Several institutional investors and hedge funds have recently made changes to their positions in the company. GF Fund Management CO. LTD. acquired a new position in Tempus AI during the fourth quarter worth approximately $108,000. Voloridge Investment Management LLC purchased a new position in shares of Tempus AI during the fourth quarter worth approximately $11,826,000. Two Sigma Advisers LP acquired a new position in shares of Tempus AI in the 4th quarter valued at $625,000. ProShare Advisors LLC acquired a new position in shares of Tempus AI in the 4th quarter valued at $244,000. Finally, Lazard Asset Management LLC purchased a new stake in Tempus AI in the 4th quarter valued at $1,034,000. 24.22% of the stock is owned by hedge funds and other institutional investors.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.